hVIVO plc (LON:HVO – Get Free Report)’s stock price rose 10% during mid-day trading on Monday . The stock traded as high as GBX 22 ($0.27) and last traded at GBX 21.25 ($0.26). Approximately 7,804,669 shares traded hands during trading, an increase of 164% from the average daily volume of 2,961,263 shares. The stock had previously closed at GBX 19.33 ($0.24).
hVIVO Stock Performance
The company has a quick ratio of 1.16, a current ratio of 1.61 and a debt-to-equity ratio of 33.86. The company has a market capitalization of £144.58 million, a PE ratio of 708.33 and a beta of 0.97. The business has a 50 day simple moving average of GBX 20.25 and a 200 day simple moving average of GBX 25.68.
hVIVO Company Profile
hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.
Featured Articles
- Five stocks we like better than hVIVO
- What Are Some of the Best Large-Cap Stocks to Buy?
- Sizing Up a New Opportunity for NVIDIA Investors
- Trading Halts Explained
- Is DeepSeek Challenging NVIDIA’s AI Dominance?
- What is a Secondary Public Offering? What Investors Need to Know
- The 3 Biggest M&A Stock Opportunities for 2025
Receive News & Ratings for hVIVO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for hVIVO and related companies with MarketBeat.com's FREE daily email newsletter.
